{
  "gold_standard": {
    "breast_cancer_her2_positive": {
      "expected_extraction": {
        "entities": [
          {
            "text": "HER2-Positive Breast Cancer",
            "type": "condition",
            "attributes": {
              "status": "positive"
            },
            "confidence": 0.95,
            "source_context": {
              "section": "conditionsModule",
              "position": "0-25",
              "context_sentence": "HER2-Positive Breast Cancer"
            }
          },
          {
            "text": "Metastatic Breast Cancer",
            "type": "condition",
            "attributes": {
              "status": "metastatic"
            },
            "confidence": 0.95,
            "source_context": {
              "section": "conditionsModule",
              "position": "26-49",
              "context_sentence": "Metastatic Breast Cancer"
            }
          },
          {
            "text": "HER2-positive metastatic breast cancer",
            "type": "condition",
            "attributes": {
              "status": "positive",
              "metastatic": true
            },
            "confidence": 0.9,
            "source_context": {
              "section": "eligibilityModule",
              "position": "25-60",
              "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer"
            }
          },
          {
            "text": "Measurable disease",
            "type": "condition",
            "attributes": {
              "status": "present"
            },
            "confidence": 0.85,
            "source_context": {
              "section": "eligibilityModule",
              "position": "61-79",
              "context_sentence": "Measurable disease per RECIST 1.1"
            }
          },
          {
            "text": "ECOG performance status 0-1",
            "type": "demographic",
            "attributes": {
              "value": "0-1",
              "scale": "ECOG"
            },
            "confidence": 0.9,
            "source_context": {
              "section": "eligibilityModule",
              "position": "80-105",
              "context_sentence": "ECOG performance status 0-1"
            }
          },
          {
            "text": "Adequate organ function",
            "type": "condition",
            "attributes": {
              "status": "adequate"
            },
            "confidence": 0.8,
            "source_context": {
              "section": "eligibilityModule",
              "position": "106-128",
              "context_sentence": "Adequate organ function"
            }
          },
          {
            "text": "Prior treatment with Trastuzumab Deruxtecan",
            "type": "exclusion",
            "attributes": {
              "status": "prior"
            },
            "confidence": 0.9,
            "source_context": {
              "section": "eligibilityModule",
              "position": "130-170",
              "context_sentence": "Prior treatment with Trastuzumab Deruxtecan"
            }
          },
          {
            "text": "Active brain metastases",
            "type": "exclusion",
            "attributes": {
              "status": "active"
            },
            "confidence": 0.9,
            "source_context": {
              "section": "eligibilityModule",
              "position": "171-193",
              "context_sentence": "Active brain metastases"
            }
          },
          {
            "text": "Pregnancy",
            "type": "exclusion",
            "attributes": {
              "status": "present"
            },
            "confidence": 0.85,
            "source_context": {
              "section": "eligibilityModule",
              "position": "194-202",
              "context_sentence": "Pregnancy or breastfeeding"
            }
          },
          {
            "text": "breastfeeding",
            "type": "exclusion",
            "attributes": {
              "status": "present"
            },
            "confidence": 0.85,
            "source_context": {
              "section": "eligibilityModule",
              "position": "206-218",
              "context_sentence": "Pregnancy or breastfeeding"
            }
          },
          {
            "text": "Trastuzumab Deruxtecan",
            "type": "medication",
            "attributes": {
              "type": "antibody-drug conjugate"
            },
            "confidence": 0.95,
            "source_context": {
              "section": "armsInterventionsModule",
              "position": "0-22",
              "context_sentence": "Trastuzumab Deruxtecan"
            }
          },
          {
            "text": "trastuzumab",
            "type": "medication",
            "attributes": {
              "type": "HER2-targeted therapy"
            },
            "confidence": 0.9,
            "source_context": {
              "section": "armsInterventionsModule",
              "position": "23-34",
              "context_sentence": "trastuzumab"
            }
          },
          {
            "text": "taxane",
            "type": "medication",
            "attributes": {
              "type": "chemotherapy"
            },
            "confidence": 0.85,
            "source_context": {
              "section": "armsInterventionsModule",
              "position": "35-41",
              "context_sentence": "taxane"
            }
          },
          {
            "text": "HER2-targeted therapy",
            "type": "treatment",
            "attributes": {
              "target": "HER2"
            },
            "confidence": 0.9,
            "source_context": {
              "section": "descriptionModule",
              "position": "30-50",
              "context_sentence": "novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer"
            }
          },
          {
            "text": "HER2-positive metastatic breast cancer",
            "type": "condition",
            "attributes": {
              "status": "positive",
              "metastatic": true
            },
            "confidence": 0.95,
            "source_context": {
              "section": "descriptionModule",
              "position": "60-95",
              "context_sentence": "patients with HER2-positive metastatic breast cancer"
            }
          },
          {
            "text": "prior trastuzumab-based therapy",
            "type": "treatment",
            "attributes": {
              "status": "prior",
              "base": "trastuzumab"
            },
            "confidence": 0.9,
            "source_context": {
              "section": "descriptionModule",
              "position": "96-125",
              "context_sentence": "progressed on prior trastuzumab-based therapy"
            }
          }
        ],
        "relationships": [
          {
            "source_entity_index": 0,
            "target_entity_index": 2,
            "relationship_type": "has_status",
            "confidence": 0.9
          },
          {
            "source_entity_index": 10,
            "target_entity_index": 15,
            "relationship_type": "is_component_of",
            "confidence": 0.8
          }
        ],
        "metadata": {
          "extraction_method": "llm_based",
          "text_length": 1200,
          "entity_count": 16
        }
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "source_entity_index": 0,
            "Mcode_element": "CancerCondition",
            "value": "HER2-Positive Breast Cancer",
            "confidence": 0.95,
            "mapping_rationale": "Primary cancer diagnosis with HER2 biomarker status"
          },
          {
            "source_entity_index": 1,
            "Mcode_element": "CancerCondition",
            "value": "Metastatic Breast Cancer",
            "confidence": 0.95,
            "mapping_rationale": "Metastatic cancer condition"
          },
          {
            "source_entity_index": 2,
            "Mcode_element": "CancerCondition",
            "value": "HER2-positive metastatic breast cancer",
            "confidence": 0.9,
            "mapping_rationale": "Specific cancer diagnosis with biomarker and metastatic status"
          },
          {
            "source_entity_index": 3,
            "Mcode_element": "CancerDiseaseStatus",
            "value": "Measurable disease present",
            "confidence": 0.85,
            "mapping_rationale": "Disease status indicating measurable disease"
          },
          {
            "source_entity_index": 4,
            "Mcode_element": "ECOGPerformanceStatus",
            "value": "0-1",
            "confidence": 0.9,
            "mapping_rationale": "ECOG performance status score range"
          },
          {
            "source_entity_index": 5,
            "Mcode_element": "Observation",
            "value": "Adequate organ function",
            "confidence": 0.8,
            "mapping_rationale": "General observation about organ function status"
          },
          {
            "source_entity_index": 10,
            "Mcode_element": "CancerRelatedMedication",
            "value": "Trastuzumab Deruxtecan",
            "confidence": 0.95,
            "mapping_rationale": "HER2-targeted antibody-drug conjugate medication"
          },
          {
            "source_entity_index": 11,
            "Mcode_element": "CancerRelatedMedication",
            "value": "Trastuzumab",
            "confidence": 0.9,
            "mapping_rationale": "Standard HER2-targeted therapy medication"
          },
          {
            "source_entity_index": 12,
            "Mcode_element": "CancerRelatedMedication",
            "value": "Taxane chemotherapy",
            "confidence": 0.85,
            "mapping_rationale": "Chemotherapy backbone medication"
          },
          {
            "source_entity_index": 13,
            "Mcode_element": "CancerRelatedMedication",
            "value": "HER2-targeted therapy",
            "confidence": 0.9,
            "mapping_rationale": "General category of HER2-targeted treatments"
          },
          {
            "source_entity_index": 14,
            "Mcode_element": "CancerCondition",
            "value": "HER2-positive metastatic breast cancer",
            "confidence": 0.95,
            "mapping_rationale": "Cancer condition from description section"
          },
          {
            "source_entity_index": 15,
            "Mcode_element": "CancerRelatedMedication",
            "value": "Trastuzumab-based therapy",
            "confidence": 0.9,
            "mapping_rationale": "Prior treatment regimen based on trastuzumab"
          }
        ],
        "unmapped_entities": [
          {
            "entity_index": 6,
            "reason": "Exclusion criteria - prior treatment is not a mCODE element for current condition"
          },
          {
            "entity_index": 7,
            "reason": "Exclusion criteria - active brain metastases is contraindication, not current condition"
          },
          {
            "entity_index": 8,
            "reason": "Exclusion criteria - pregnancy status is not a mCODE oncology element"
          },
          {
            "entity_index": 9,
            "reason": "Exclusion criteria - breastfeeding status is not a mCODE oncology element"
          }
        ],
        "metadata": {
          "mapping_method": "llm_based",
          "total_entities": 16,
          "mapped_count": 12,
          "unmapped_count": 4
        }
      }
    }
  }
}